About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Thursday, August 14th, 2014

The QualityStocks
Daily Stock List


ImageWare Systems, Inc. (IWSY)

Wall Street Resources and Wall Street Daily reported on ImageWare Systems, Inc. (IWSY), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Headquartered in San Diego, California, ImageWare Systems, Inc. is an identity innovator that has provided advanced biometric solutions to traditional identity markets for over 10 years. The Company is a leading developer of mobile and cloud-based identity management solutions, providing biometric, secure credential, and law enforcement technologies. Its biometric product line is scalable for global deployment. It includes a multi-biometric engine that is hardware and algorithm independent, allowing the enrollment and management of unlimited population sizes.

ImageWare’s identification products are used to manage and issue secure credentials, including national IDs, passports, driver's licenses, smart cards, and access control credentials. The Company’s digital booking products provide law enforcement with integrated mug shot, fingerprint livescan, and investigative capabilities. ImageWare’s products include its IWS Biometric Engine®. It is the first and only truly multi-modal, device- and algorithm- independent biometric software platform. The Company’s re-engineered IWS Biometric Engine® 2.0, combines considerably enhanced performance and wider scalability with an SOA architecture. Therefore, this makes it possible to offer cloud-based biometric identity management services.

In addition, ImageWare has its EPI Builder®. It provides the basis for a multi-modal biometric capture platform, which ensures device interoperability and support for centralized and distributed deployment models. The Company also has its GoCloudID.com. GoCloudID.com is a highly modular, SOA-based software platform that delivers a first-rate ability to quickly develop and deploy highly secure, yet flexible standards based identity solutions. These solutions constantly adapt to evolving customer requirements and developing market demands.

Moreover, ImageWare Systems is using its proven multi-modal biometric advances to deliver innovative mobile capabilities to the wireless, financial services, and healthcare sectors. The PillPhone®, enabled by ImageWare’s GoMobile interactive push application platform, is Food and Drug Administration (FDA) cleared and the only mobile health management application secured by biometrics.

The Company’s next-generation cloud identity management and authentication service is GoMobile Interactive™ (GMI). GMI is a cloud-based, multi-modal biometric mobile identity management solution. It enables messaged based premier identity verification for existing and new mobile banking, mobile wallet, and other mobile applications that require a next-generation method to automate and verify the identity of the customer. GoMobile Interactive is constructed upon the award winning IWS Biometric Engine® (IWS BE), an SOA based server platform, which enables advanced biometric data process and management with ESB connectivity.

This week, ImageWare Systems issued a corporate update. Operational highlights for the Company include being awarded a $1.0 million contract to implement a multi-modal biometric driver license system for the state of Baja California, Mexico. ImageWare also reached a three-year agreement in principle with a major global retailer to provide multi-modal biometric identity management on the Fujitsu Cloud.

ImageWare Systems, Inc. (IWSY), closed Thursday's trading session at $2.35, down 0.84%, on 227,993 volume with 173 trades. The average volume for the last 60 days is 113,601 and the stock's 52-week low/high is $1.17/$2.63.

RegeneRx Biopharmaceuticals, Inc. (RGRX)

SmarTrend Newsletters reported previously on RegeneRx Biopharmaceuticals, Inc. (RGRX), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

RegeneRx Biopharmaceuticals, Inc. is a clinical-stage drug development company headquartered in Rockville, Maryland. It focuses on tissue protection, repair and regeneration with an extensive portfolio of product candidates for first-in-class therapeutic peptides. RegeneRx’s mission is to research and develop novel pharmaceuticals that protect and repair tissue and organ damage caused by disease, trauma or other pathology. RegeneRx holds multiple issued patents or filed patent applications worldwide to enable and protect multiple indications and applications for its product candidates. The Company is based in Rockville, Maryland.

RegeneRx Biopharmaceuticals is centering on the development of Thymosin beta 4 (a novel therapeutic peptide), for tissue and organ protection, repair and regeneration.
The Company’s management team is focusing on moving three distinct Tβ4-based drug candidates through the clinic. These are RGN-137, RGN-259 and RGN-352. RGN-137 is a topical gel formulation of the peptide Tβ4. RegeneRx is developing this as a novel treatment to hasten dermal healing.

RGN-259 is a Tβ4-based sterile eye drop. The Company is developing this as a novel treatment for corneal healing. In addition, RegeneRx is developing RGN-352, an injectable product for the treatment of cardiac tissue damage post-acute myocardial infarction and the management of multiple sclerosis.

In April,  RegeneRx announced that it received a Notice of Allowance for a second U.S. patent for treating central nervous system injuries and disorders using Thymosin beta 4 (Tβ4) to regenerate damaged tissue. In this case, the patent will be for the treatment of patients suffering a stroke. Researchers at the Henry Ford Hospital in Detroit, Michigan, discovered Tβ4’s effects in animal studies performed under a Material Transfer Agreement between the Institution and RegeneRx Biopharmaceuticals. RegeneRx has received a license to the intellectual property and the patent will expire in 2026.

Last month, RegeneRx announced that a new paper entitled, Thymosin β4 Prevents Cardiac Rupture and Improves Cardiac Function in Mice with Myocardial Infarction, was published in the journal, Heart Circulation Physiology, on July 11, 2014. The new report indicates that Thymosin β4 prevents heart rupture & improves cardiac function after heart attack in mice. Animals were treated with Tβ4 daily at a relatively low dose for 7 days using a mini-pump implant. Treatment with Tβ4 ameliorated left ventricular dilation, improved cardiac function, and decreased the mortality rate due to cardiac rupture. Treatment also considerably improved cardiac function after MI.

RegeneRx Biopharmaceuticals, Inc. (RGRX), closed Thursday's trading session at $0.1399, down 6.73%, on 137,950 volume with 24 trades. The average volume for the last 60 days is 36,838 and the stock's 52-week low/high is $0.043/$0.285.

CannaVest Corp. (CANV)

SmallCapVoice, ProfitableTrading, TopStockAnalysts, Greenbackers, Flagler Financial Group, Money Morning, InvestorPlace, Market Authority, and smartOTC reported on CannaVest Corp. (CANV), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

CannaVest Corp. engages in developing, producing, marketing and selling end consumer products to the nutraceutical industry containing the hemp plant extract, Cannabidiol (CBD). CBD undergoes refining into the Company’s own PlusCBD Oil™ brand.  The Company also engages in reselling to third parties raw product acquired by it pursuant to its supply relationships in Europe. CannaVest’s shares trade on the OTC Markets’ OTCQB. The Company has its headquarters in Las Vegas, Nevada.

CannaVest’s plan is to diversify its business chiefly into four operating segments. These include securing and supplying raw hemp product for sale to third parties; developing, producing, marketing and selling consumer products to the nutraceutical industry containing CBD; establishing and helping others to establish farming operations focused on the growth of industrial hemp; and investing in companies in its industry.

CannaVest subsidiaries include CannaVest Laboratories. This subsidiary facilitates innovative research and develops nutraceutical and food products, containing cannabidiol (CBD) oil. CannaVest Laboratories is the developer and manufacturer of CannaVest’s own award winning CBD Simple™. CannaVest Laboratories is equipped with state of the art high-performance equipment and distillation tools to produce award winning CBD Simple™, and PlusCBD™ Oil.

Subsidiary US Hemp Oil, LLC provides seed procurement, cultivation, processing, and production consultation; and equipment to support U.S. farmers, researchers and businesses to cultivate and process industrial hemp in the United States. US Hemp Oil plans to construct seed-processing mills and bring hemp based products to market.

In late July, CannaVest announced that it was awarded first place in the CBD concentrate category at the 2014 Michigan Medical Cannabis Cup, in Clio, Michigan on July 27, 2014. The Company’s proprietary pharmaceutical grade CBD concentrate, CBD Simple™, consistently achieves the highest CBD concentration in the industry. It has won this category in the High Times Cannabis Cup a record four times. Furthermore, CannaVest was awarded first place in the 2013 Michigan Green Cup, also in the CBD Concentrate category.

CannaVest Corp. (CANV), closed Thursday's trading session at $3.26, up 24.90%, on 1,137,623 volume with 1,846 trades. The average volume for the last 60 days is 75,700 and the stock's 52-week low/high is $1.94/$201.00.

Strategic Environmental & Energy Resources, Inc. (SENR)

Today we are reporting on Strategic Environmental & Energy Resources, Inc. (SENR), here at the QualityStocks Daily Newsletter.

Strategic Environmental & Energy Resources, Inc. (SEER) is a top provider of patented and proprietary technologies and services to the renewable fuels, waste management, and oil and gas industries. The Company has three wholly-owned operating subsidiaries. These are REGS, LLC (Resource Environmental Group Services), Tactical Cleaning Company, LLC, and MV Technologies, LLC. SEER also has two majority-owned subsidiaries: Paragon Waste Solutions, LLC; and ReaCH4biogas (Reach). SEER has begun an aggressive manufacturing program. It has multiple units undergoing construction to fulfill current and anticipated demand in several vertical markets.  

The REGS subsidiary provides industrial and environmental services to the petroleum industry, different industrial and manufacturing clients, medical facilities, universities, government entities, and environmental and consulting firms in the Western U.S. SEER’s Tactical Cleaning is a premier provider of service solutions to owners and operators of railcars, tanker trucks, frac tanks, and vac boxes. 

SEER’s MV Technologies solves H2S (Hydrogen Sulfide) challenges. MV Technologies has been supplying its H2SPlus™ systems to a wide variety of industries for over 10 years. SEER’s Paragon Waste Solutions affiliate is a developer of patent-pending waste destruction technology.

Last month, SEER announced its MV Technologies subsidiary was awarded a $799,000 contract for an installation of its OdorFilter™ System to control process gases at a large asphalt handling facility in the western United States. MV's OdorFilter™ technology is an innovative combination of chemical and biological reactions and other integrated and proprietary engineered elements. This is to provide a highly effective solution to the complex issues being addressed by the asphalt and other industries.

This week, SEER announced results for its second quarter and six-month period ended June 30, 2014. Total Q2 revenue increased 46 percent to a record $4.3 million from $2.9 million in Q2 2013. For Q2, net income attributable to common stockholders increased to a record $464,600, or $0.01 per share, from a net loss of $17,300, or less than one cent per share, in Q2 2013. 

Regarding six-month results, revenue in the first half of 2014 increased 28 percent to $7.1 million from $5.5 million in the same period last year. Net loss attributable to stockholders through six months was $570,600, or $0.01 per share, in comparison to $188,800, or less than one cent per share, in the same period in 2013.

Strategic Environmental & Energy Resources, Inc. (SENR), closed Thursday's trading session at $1.10, up 4.76%, on 19,550 volume with 9 trades. The average volume for the last 60 days is 39,242 and the stock's 52-week low/high is $0.73/$1.72.

Bioheart, Inc. (BHRT)

SmallCapVoice reported recently on Bioheart, Inc. (BHRT), and we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Bioheart, Inc.’s commitment is to maintaining its leading position within the cardiovascular sector of the cell technology industry. The Company delivers cell therapies and biologics. These help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions, and other issues. Its lead product is MyoCell®. Bioheart lists on the OTCQB and the Company is based in Sunrise, Florida.

Bioheart’s goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations. Pertaining to biotechnology, the Company is centering on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease.

Its MyoCell® product is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells to improve cardiac function in chronic heart failure patients. Its MyoCell® therapy consists of myoblasts that are injected into the scar tissue, which has formed in the hearts of patients suffering from heart failure. The increased muscle formed by MyoCell® in these patients’ hearts has been shown to lead to improved cardiac function and an improved quality of life.

Bioheart announced this past May an update on the phase I safety trial using adipose derived cells. Its AdipoCell™ product is currently undergoing study in a variety of indications. These include erectile dysfunction, chronic obstructive pulmonary disease and dry macular degeneration. Approximately four years ago, Bioheart began a study using adipose derived stem cells (AdipoCell™) in congestive heart failure patients. The patients were recently contacted to assess quality of life. The patients have reported that they are in good spirits and doing well.

Recently, Bioheart announced that it completed the world's first combination stem cell treatment with Magnum Cell Therapies in Honduras. A patient with congestive heart failure was treated with a combination of AdipoCell™ or adipose derived stem cells and MyoCell® or muscle derived stem cells. AdipoCell may help to promote angiogenesis or new blood vessel formation in ischemic tissue. MyoCell may help to promote myogenesis or new muscle formation. The cells were delivered directly into the damaged areas of the heart using the MyoCath® Catheter.

Bioheart, Inc. (BHRT), closed Thursday's trading session at $0.0275, down 4.84%, on 522,400 volume with 25 trades. The average volume for the last 60 days is 1,297,079 and the stock's 52-week low/high is $0.0063/$0.08.


The QualityStocks
Company Corner


One World Holdings, Inc. (OWOO)

The QualityStocks Daily Newsletter would like to spotlight One World Holdings, Inc. (OWOO). Today, One World Holdings, Inc. closed trading at $0.03, even for the day, on 411,668 volume with 41 trades. The stock’s average daily volume over the past 60 days is 159,974, and its 52-week low/high is $0.015/$3.6154.

One World Holdings, Inc. announced that its subsidiary, The One World Doll Project (OWDP), is excited to announce its newly launched distribution of the Prettie Girls!™ multicultural fashion play dolls, now available online at Toysrus.com. As America becomes increasingly culturally diverse, it is important for children to have a variety of options when selecting toys.

One World Holdings, Inc. (OWOO) subsidiary, The One World Doll Project, was established in 2010 to make a significant positive cultural impact through the doll category, transcending global and ethnic borders to create positive self-image in young women and girl around the world. Led by worldwide famous doll designer Stacy McBride-Irby, The One World Doll Project team has more than 50 collective years in the doll and toy industry and is dedicated and armed with the experience to ensure that the dolls are of the highest quality and value.

In 2013, the company released its Prettie Girls!™ line of multi-cultural fashion dolls uniquely designed with individual physical attributes, personal stories and hobbies, and goals and inspirations. For young girls, the dolls are a friend, a partner in play, and a glimpse of their biggest, brightest dreams. For young women, the dolls are a symbol of who they are and what they can achieve. For doll connoisseurs, The One World Doll Project promises stylish works of art that will become a vital part of a growing collectors’ market.

The One World Doll Project also has a Signature Celebrity Collection of Prettie Girls! and in 2013 released its first celebrity collectors doll modeled after supermodel Cynthia Bailey from The Real Housewives of Atlanta. Since the release of the doll, it has been showcased with Synthia on The Arsenio Hall Show, What Happens Live with Andy Cohen and The Bethenny Show.

Using a web-based sales model, One World Holdings plans to quickly capture significant market share in the dolls and stuffed toys space. After securing a strong online presence, the company will focus on brick and mortar retailing as it moves toward the ultimate pursuit of expanding worldwide. The company has established distribution deals with Toys “R” Us, HEB, dollgenie.com, Tuckers Toy Shop, pattycakedoll.com, and has recently expanded its retail presence internationally with the People’s Pharmacy storechain in the Central American country of Belize. The Prettie Girls! Dolls have been featured in national and international media spotlights like CNN, The Wall Street Journal, Jet Magazine, Bloomberg.com, Parade.com, Dolls Magazine, The Toy Book, The Houston Chronicle and Houston Business Journal, and TheStreet.com. Disclaimer

One World Holdings, Inc. Company Blog

One World Holdings, Inc. News:

The One World Doll Project Announces New Online Distribution With Toys"R"UsŪ

Ten Additional H-E-B Stores to Carry The Prettie Girls! Dolls; Meeting With 80 Store Managers Helps to Accelerate Distribution

Renowned Doll Designer Robert Tonner Endorses One World Dolls; Stating an Interest in Collaboration

Consorteum Holdings, Inc. (CSRH)

The QualityStocks Daily Newsletter would like to spotlight Consorteum Holdings, Inc. (CSRH). Today, Consorteum Holdings, Inc. closed trading at $0.0063, up 103.23%, on 1,546,067 volume with 9 trades. The stock’s average daily volume over the past 60 days is 342,271, and its 52-week low/high is $0.0031/$0.02.

Consorteum Holdings, Inc. (CSRH) has spent the last 3 years developing relationships and licensing agreements to take the center stage in the emerging market of mobile gaming. The company has the capability to deliver rich mobile content to end users who will use their smart phones in ways that could not even have been imagined five years ago.

Specializing in delivery of mobile content, mobile payment solutions and products through a mix of on-deck partnerships, license agreements, and joint venture revenue share arrangements, the company operates as a technology and services aggregator to meet the diverse needs of its client base. This approach enables unparalleled flexibility when sourcing solutions, resulting in smarter, faster deployment of technologies, competitive pricing, and potential for new streams of revenue.

ThreeFiftyNine Inc., a wholly owned subsidiary, hired a software development team that had previously designed the world’s first regulatory compliant mobile platform for delivery of gaming content created by a third party. The platform, which has met the rigorous standards of the Nevada Gaming Board, the gold standard in regulatory gaming, represents the first generation software delivery platform for mobile devices. The development team spent the past 5 years and millions of dollars in non-recurring engineering costs to complete the development of the platform. At the heart is the capability to deliver any digital content across any cellular network to any mobile device. This key differentiator makes it possible for Consorteum to approach many different markets that are in the business of providing mobile connectivity and mobile content.

Consorteum’s mobile initiatives will benefit multiple business verticals. The company has strategically designed its business initiatives to create repetitive transactions on an ongoing basis. Consorteum's goal is to have their customers think of them more as partners, rather than just technology providers, for longer-lasting, more profitable relationships. Disclaimer

Consorteum Holdings, Inc. Company Blog

Consorteum Holdings, Inc. News:

Consorteum Holdings Signs Mobile Application Development Contract With Bet Butler Limited

Consorteum Holdings Launches New Mobile Results App for Popular Keno Game

Consorteum Holdings Enters Mobile Application Development and Business Agreement With XpertX, Inc.

Big Tree Group, Inc. (BIGG)

The QualityStocks Daily Newsletter would like to spotlight Big Tree Group, Inc. (BIGG). Today, Big Tree Group, Inc. closed trading at $0.0125, up 4.17%, on 2,023,229 volume with 34 trades. The stock’s average daily volume over the past 60 days is 524,788, and its 52-week low/high is $0.0105/$0.45.

Big Tree Group, Inc. (BIGG) is an authorized sales agent for thousands of toy manufacturers in China, providing multiple procurement services for international toy distributors and wholesalers. Headquartered in Shantou City, known as the Toy Capital of the world, Big Tree operates a 21,000-square-foot showroom to display its products to thousands of international toy purchasers. The sprawling facility includes an onsite testing laboratory where all toys undergo rigorous testing to ensure both quality and function before reaching the showroom floor.

Big Tree is a “one-stop-shop” for the international sourcing and distribution of toys and other related products. As an authorized agent, Big Tree currently represents more than 8,000 toy manufacturers, offering more than 300,000 varieties of toy products such as remote control toys, digital toys, sports toys, play sets, educational toys, dolls and infant toys. Big Tree conducts its operations through its two fully operating subsidiaries, Big Tree Brunei and Big Tree Shantou.

In 2011, Big Tree began selling its own patented construction toy, the Magic Puzzle (3D). The proprietary Big Tree Magic Puzzle is promoted and distributed solely in the Chinese domestic market, available through Big Tree Shantou’s online store and at several retail locations. The product has been well-received, and Big Tree is also evaluating global marketing and distribution of the Magic Puzzle.

Big Tree’s operations are spearheaded by long-time China toy industry veteran and company CEO Wei Lin, who founded the toy export and import company Shantou Dashu Toy Corp. Ltd. He is supported by a seasoned and experienced management team proficient in operations management, marketing, sales, team management, education and accounting. This leadership team has established an aggressive growth strategy to expand Big Tree’s sales and global product distribution by utilizing its expansive multi-lingual sales team and by leveraging industry contacts to identify strategic mergers and acquisitions, and maximize trade and industry opportunities.

As the world’s leading toy manufacturer and exporter, China produces and distributes two-thirds of the multi-billion dollar toy industry’s global demand. The nation’s manufacturing is highly regional, with 70 percent of toy sales in China generated in the Guangdong province. Strategically located in this province, Big Tree has cultivated an extensive customer base in Asia and Europe and is planning global expansion and distribution, especially in the Americas. Disclaimer

Big Tree Group, Inc. Company Blog

Big Tree Group, Inc. News:

Market Advisors, Inc. Issues Report on Big Tree Group

Big Tree Group Launches New Domestic Online Ecommerce Platform

Big Tree Group Receives Purchase Orders from Costa Rican Retail Chain Valued at Approximately $400,000

VistaGen Therapeutics, Inc. (VSTAD)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTAD). Today, VistaGen Therapeutics, Inc. closed trading at $0.60, even for the day. The stock’s average daily volume over the past 60 days is 152, and its 52-week low/high is $0.25/$0.89.

VistaGen Therapeutics, Inc. (VSTAD) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs

VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.

By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.

Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.

AV-101, VistaGen's lead small molecule prodrug candidate, has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.

VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer

VistaGen Therapeutics, Inc. Company Blog

VistaGen Therapeutics, Inc. News:

VistaGen Receives Notice of Allowance for Canadian Patent Expanding Stem Cell Technology Platform

VistaGen Joins HESI's Cardiac Safety Committee and Working Groups

VistaGen Receives Notice of Allowance for U.S. Patent Expanding Stem Cell Technology Platform for Drug Rescue and Regenerative Medicine

Armco Metals Holdings, Inc. (AMCO)

The QualityStocks Daily Newsletter would like to spotlight Armco Metals Holdings, Inc. (AMCO). Today, Armco Metals Holdings, Inc. closed trading at $0.17, off by 1.15%, on 235,883 volume with 148 trades. The stock’s average daily volume over the past 60 days is 503,987, and its 52-week low/high is $0.159/$0.58.

Armco Metals Holdings, Inc. (AMCO), since its founding 10 years ago, has tirelessly worked to create low-cost, high-quality solutions to meet steel industry demands and achieve its goal to become the largest scrap steel recycler in China. The company operates through five subsidiaries located in key regions throughout the country to source, import, process, and distribute quality, environmentally friendly recycled scrap steel, as well as metal and non-ferrous metal ore.

Subsidiaries Armco Metals International, Ltd., Armco (Lianyungang) Renewable Metals, Inc., Armet (Lianyungang) Holdings, Inc., Henan Armco & Metawise Trading Co., Ltd., Armco Metals (Shanghai) Holding, Ltd. support Armco Metal’s overarching corporate mission and operate to provide the country’s steel production industry with sustainable, responsible solutions to its material needs. Aligned with China’s green initiatives, Armco Metals and its subsidiaries are helping the government reach its scrap metal consumption goal of 20% by 2015.

Leveraging long-standing relationships with more than 10 international metal suppliers, more than 100 small- and medium-sized Chinese steel production companies, and some of the country’s large state-run foundries, Armco Metals benefits from a steady and dependable supply of demand for the company’s high-quality product known for excellent market values.

Armco Metals’ management team has established a unique approach to business and environment by providing responsible solutions based on environmentally friendly practices; reliable, cost-effective sourcing; and quality metal products. Backed by more than 10 years of industry experience, company executives have successfully positioned the company as credible, dependable partner for customers, suppliers, and investors within the steel production market. Disclaimer

Armco Metals Holdings, Inc. Company Blog

Armco Metals Holdings, Inc. News:

China's Ministry of Industry and Information Technology Approves Subsidiary

Armco Metals Holdings, Inc. Receives Government Approval to Import 20,000 Metric Tons of Restricted Materials Annually

Armco Metals Holdings, Inc. Receives $15 Million Credit Approval From a Chinese Commercial Bank


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



Real Pennies





By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251